← back to search

Tim Forshew

Neogen Europe (United Kingdom) · GB
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer Genomics and Diagnostics, Cancer, Hypoxia, and Metabolism, and Ubiquitin and proteasome pathways.
h-index
32
citations
9,291
works
143
NIH funding
primary concept
email

Recent publications

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
EMBO Molecular Medicine 2018cited by 93position: middledoi
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer
Scientific Reports 2017cited by 113position: middledoi
MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma
Development 2017cited by 79position: middledoi
Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection
Cancer Medicine 2017cited by 35position: lastdoi
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome
Annals of Oncology 2015cited by 52position: middledoi
Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing
Journal of Molecular Diagnostics 2015cited by 28position: middledoi
Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform.
Journal of Clinical Oncology 2015cited by 3position: middledoi
935 The Timing of Oncogenic Events in the Evolution of the Oesophageal Adenocarcinoma Genome and Implications for Clinical Diagnostics
Gastroenterology 2014cited by 0position: middledoi
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
New England Journal of Medicine 2013cited by 2,195position: middledoi
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Nature 2013cited by 1,595position: middledoi
Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer
Cancer Cell 2013cited by 462position: middledoi
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Science Translational Medicine 2012cited by 1,311position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Nitzan Rosenfeld · Queen Elizabeth Hospital6 papers (2012–2018)Davina Gale · AstraZeneca (United Kingdom)5 papers (2012–2018)Dana W.Y. Tsui · Memorial Sloan Kettering Cancer Center5 papers (2012–2018)Muhammed Murtaza · University of Wisconsin System4 papers (2012–2018)Carlos Caldas · Concern Foundation4 papers (2012–2018)Sean Humphray · University of Minnesota, Twin Cities3 papers (2013–2015) · 3 papers (2015–2017)James D. Brenton · University of Cambridge3 papers (2012–2015)Francesco Marass · SIB Swiss Institute of Bioinformatics3 papers (2013–2018)Sarah‐Jane Dawson · AGRF Ltd3 papers (2012–2013)Christopher G. Smith · University of Cambridge2 papers (2017–2018)James Morris · Cardiff and Vale University Health Board2 papers (2017–2018) · 2 papers (2013–2018)Zoya Kingsbury · University of Minnesota, Twin Cities2 papers (2013–2015)Dineika Chandrananda · The University of Melbourne2 papers (2017–2018)Vincent Plagnol · Genomics (United Kingdom)2 papers (2015–2017)James Hadfield · AstraZeneca (United Kingdom)2 papers (2012–2013) · 2 papers (2013–2015)David Bentley · Centre for Human Genetics2 papers (2012–2013)Oscar M. Rueda · University of Cambridge2 papers (2013–2018)